Epiliquid

Epiliquid is a seed-stage biotechnology company founded in 2021 in Mendoza, Argentina, that develops a liquid biopsy platform for early cancer detection and management. The company's technology uses methylation-based biomarkers and other specific molecular signals detected from blood samples to identify cancer at early stages, making diagnostics accessible and affordable for a broader population. Epiliquid's platform is designed for high sensitivity and specificity, targeting colorectal cancer and other tumor types. Its multidisciplinary team combines scientific research from academia with private innovation to translate bench research into clinically validated diagnostic tools. The company's customers include healthcare providers and research institutions seeking non-invasive, low-cost alternatives to traditional tissue biopsy for oncology diagnostics.